Zeria Pharmaceutical Co., Ltd. (TYO:4559)
Japan · Delayed Price · Currency is JPY 2,061.00
-8.00 (-0.39%)
Aug 4, 2026, 11:22 AM JST
Zeria Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 27,760 | 23,592 | 20,323 | 16,219 | 11,704 |
Cash & Short-Term Investments | 27,760 | 23,592 | 20,323 | 16,219 | 11,704 |
Cash Growth | 17.67% | 16.09% | 25.30% | 38.58% | 19.48% |
Receivables | 30,790 | 26,611 | 21,080 | 17,419 | 16,153 |
Inventory | 20,896 | 16,433 | 14,489 | 12,764 | 11,950 |
Other Current Assets | 3,200 | 2,893 | 1,917 | 1,801 | 1,856 |
Total Current Assets | 82,646 | 69,529 | 57,809 | 48,203 | 41,663 |
Property, Plant & Equipment | 27,599 | 26,641 | 26,517 | 24,591 | 23,139 |
Long-Term Investments | 29,785 | 22,541 | 22,957 | 20,172 | 18,165 |
Goodwill | 3,027 | 3,621 | 4,262 | 5,299 | 5,830 |
Other Intangible Assets | 36,554 | 36,740 | 38,877 | 36,631 | 35,376 |
Long-Term Deferred Tax Assets | 84 | 97 | 110 | 136 | 108 |
Other Long-Term Assets | 2 | 2 | 1 | 2 | 1 |
Total Assets | 179,697 | 159,171 | 150,533 | 135,034 | 124,282 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 4,895 | 3,971 | 3,273 | 1,996 | 2,049 |
Accrued Expenses | 1,778 | 1,623 | 1,584 | 1,554 | 1,530 |
Short-Term Debt | 33,834 | 34,298 | 38,283 | 34,890 | 33,842 |
Current Income Taxes Payable | 4,827 | 3,773 | 1,967 | 749 | 458 |
Other Current Liabilities | 10,374 | 10,784 | 9,411 | 7,969 | 6,314 |
Total Current Liabilities | 55,708 | 54,449 | 54,518 | 47,158 | 44,193 |
Long-Term Debt | 5,269 | 6,865 | 7,943 | 14,541 | 18,385 |
Pension & Post-Retirement Benefits | 201 | 224 | 458 | 234 | 1,073 |
Long-Term Deferred Tax Liabilities | 8,586 | 6,496 | 6,447 | 5,190 | 3,905 |
Other Long-Term Liabilities | 1,329 | 1,341 | 1,339 | 2,232 | 1,635 |
Total Liabilities | 71,093 | 69,375 | 70,705 | 69,355 | 69,191 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 6,593 | 6,593 | 6,593 | 6,593 | 6,593 |
Additional Paid-In Capital | 5,620 | 11,685 | 11,685 | 11,685 | 11,685 |
Retained Earnings | 73,545 | 67,207 | 59,254 | 53,462 | 48,860 |
Treasury Stock | -12,204 | -18,266 | -18,265 | -18,264 | -17,593 |
Comprehensive Income & Other | 34,842 | 22,320 | 20,355 | 11,973 | 5,349 |
Total Common Equity | 108,396 | 89,539 | 79,622 | 65,449 | 54,894 |
Minority Interest | 208 | 257 | 206 | 230 | 197 |
Shareholders' Equity | 108,604 | 89,796 | 79,828 | 65,679 | 55,091 |
Total Liabilities & Equity | 179,697 | 159,171 | 150,533 | 135,034 | 124,282 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 39,103 | 41,163 | 46,226 | 49,431 | 52,227 |
Net Cash (Debt) | -11,343 | -17,571 | -25,903 | -33,212 | -40,523 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -257.33 | -398.62 | -587.64 | -751.86 | -897.74 |
Filing Date Shares Outstanding | 44.08 | 44.08 | 44.08 | 44.08 | 44.21 |
Total Common Shares Outstanding | 44.08 | 44.08 | 44.08 | 44.08 | 44.41 |
Working Capital | 26,938 | 15,080 | 3,291 | 1,045 | -2,530 |
Book Value Per Share | 2459.11 | 2031.31 | 1806.31 | 1484.77 | 1236.08 |
Tangible Book Value | 68,815 | 49,178 | 36,483 | 23,519 | 13,688 |
Tangible Book Value Per Share | 1561.16 | 1115.67 | 827.66 | 533.55 | 308.22 |